Oct 13 Neurovive Pharmaceutical AB
* Neurovive discontinues development of CicloMulsion for acute kidney injury
* Says today announced results from the exploratory clinical phase II study CiPRICS.
* Says results clearly show that patients treated with CicloMulsion prior to open heart surgery experience no benefit compared to placebo in the prevention of acute kidney injury (AKI) Source text for Eikon: Further company coverage: (Stockholm Newsroom)
Aixtron, Fujian to explore what is left of deal after U.S. veto
FRANKFURT, Dec 3 German semiconductor equipment maker Aixtron will explore with its Chinese suitor what can be salvaged of the planned takeover after a U.S. presidential order ruled the deal posed a national security risk, the company said on Saturday.
UPDATE 2-Trump moves to quickly fill his top Cabinet ranks
NEW YORK, Dec 2 U.S. President-elect Donald Trump said he expected to have most members of his Cabinet announced next week, interviewing more candidates at Trump Tower for top jobs in his administration as he prepares to take office on Jan. 20.